Faes Farma

Base business recovers in Q2; FY21 outlook reiterated despite resurfacing COVID-19 concerns

28/07/21 -"On softer comps, Faes witnessed some recovery in the base business in Q2 21. While resurfacing COVID-19 concerns and Bilastine’s recent patent loss in Spain does signal a tricky period ahead, one ..."

Published on
You may also be interested by these reports :
Our SOTP valuation was clearly helped by the higher multiple reference that we now apply to Life Science, lifting the EV/EBIT multiple from 18.0x to ...

Merck’s investors day was impressive. The company’s management was very positive about the group’s future performance as a whole and by the ...

Soon after our last teaser (GENMAB’S LIFE BEYOND DARZALEX) in May 2020, Genmab (Reduce, Denmark) announced a big oncology pact with AbbVie (US pharma ...

Our target price is a beneficiary of both near-term tailwinds and solid longer-term fundamentals. While our near-term earnings benefit on the back of ...


Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis


AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO